Expects Foundry revenue of at least $175M in 2023, excluding the impact of any downstream value share revenue, although Ginkgo is still working toward the achievement of downstream value share in 2023. While Biosecurity remains an uncertain business, Ginkgo expects Biosecurity revenue in 2023 of at least $100M, with nearly half of this revenue expected to come from emerging product lines that are more recurring in nature.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on DNA:
- Ginkgo Bioworks Reports Fourth Quarter and Full Year 2022 Financial Results
- Ginkgo Bioworks options imply 10.1% move in share price post-earnings
- Ginkgo Bioworks, Zymtronix announce partnership
- Ginkgo Bioworks to lead pathogen monitoring program at Kigali Airport, Rwanda
- Cathie Wood Gets Back on Track; Here Are 2 Stocks She’s Snapping Up
